Obagi Medical Products’s Neutral Rating Reaffirmed at Piper Jaffray (OMPI)
Piper Jaffray reiterated their neutral rating on shares of Obagi Medical Products (NASDAQ: OMPI) in a research note issued to investors on Friday. The firm currently has a $13.00 target price on the stock, up from their previous target price of $12.00.
“Obagi reported 4Q12 adjusted diluted EPS of $0.15 (including $1.7M of spending related to the ongoing build-out of the company’s e-commerce platform), beating the Street estimate of $0.14. Revenues were in line with the Street, with Nu-Derm up 4% over 4Q11. The growth outlook however is murky in our view given that Allergan (via its SkinMedica unit) launched a non-hydroquinone-based skin lightening product in January 2013. Given the competitive dynamics surrounding Nu-Derm and the added expense and questionable benefits associated with the e-commerce platform in our view, we believe the outlook for sustainable longer-term earnings growth is uncertain.,” Piper Jaffray’s analyst wrote.
Obagi Medical Products (NASDAQ: OMPI) traded down 0.33% on Friday, hitting $14.9901. Obagi Medical Products has a 1-year low of $10.70 and a 1-year high of $18.00. The stock’s 50-day moving average is currently $14.07. The company has a market cap of $261.2 million and a price-to-earnings ratio of 16.71.
Separately, analysts at Cantor Fitzgerald upgraded shares of Obagi Medical Products from a hold rating to a buy rating in a research note to investors on Friday. They now have a $19.00 price target on the stock, up previously from $15.00.
Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $15.67.
Obagi Medical Products, Inc. is a specialty pharmaceutical company that develops, markets and sells, and is a provider of topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.